Specify a stock or a cryptocurrency in the search bar to get a summary
BiVictriX Therapeutics PLC
BVXBiVictriX Therapeutics plc, a biotechnology company, engages in the research and experimental development of pharmaceutical products in the United Kingdom. The company develops Bi-Cygni, a proprietary platform that combines the discovery of novel, cancer-selective twin-antigen pairs or fingerprints with bispecific antibody engineering insights to create anti-cancer therapeutics. Its lead program is BVX001, a first-in-class Bi Cygni antibody drug conjugates to treat acute myeloid leukemia. The company also develops BVX002 for treating ovarian and other solid tumors; and BVX003 for bladder and other solid tumors. The company was formerly known as BiVictriX plc and changed its name to BiVictriX Therapeutics plc in August 2021. BiVictriX Therapeutics plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom. Address: Mereside, Macclesfield, United Kingdom, SK10 4TG
Analytics
WallStreet Target Price
5 099 GBXP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BVX
Dividend Analytics BVX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BVX
Stock Valuation BVX
Financials BVX
Results | 2019 | Dynamics |